Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Neuroleptic

or Sedative-hypnotic

or [[:Category:Expectorants|Expectorant]]

Use the filters below to narrow your results.

None (9) · (none, never marketed) (1) · Clozaril (1) · Dalmane (1) · Doral (1) · Doriden (1) · Fanapt (1) · Geodon (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Lunesta (1) · Mellaril (1) · Moban (1) · Mogadon (1) · Mucinex, Robitussin, Tussin (1) · Navane (1) · Nembutal (1) · Orap (1) · Placidyl (1) · Prolixin (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Saphris (1) · Seconal (1) · Sonata (1) · Stelazine (1) · THIP (1) · Thorazine (1) · Trilafon (1) · Versed (1) · Xyrem (1)

None (2) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator (15) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator (1) · GABAA potentiator and direct activator (2) · GABAB agonist; GHB receptor agonist (1) · Melatonin receptor agonist (2) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · Phenothiazine D2 antagonist (4) · Positive allosteric modulator of the GABAA receptor at the benzodiazepine binding site; increases frequency of Cl− channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) · Selective GABAA agonist (extrasynaptic delta subunit) (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1)

None (45) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"' (1)

None (45) · 200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (45) · 100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (45) · 2.4 g/d (1) · N/A (never approved) (1)

None (45) · intranasal; rectal and IV reported. (1) · Oral (2) · sublingual (1)

None (45) · 30 minutes (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (45) · 4 hours (IR); 12 hours (ER) (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1)

None (45) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~1 hour'"`UNIQ--ref-00001050-QINU`"' (1)

None (45) · High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) · Not formally characterized in humans. (1)

None (45) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Generally considered acceptable.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

A

B

C

D

E

F

G

I

L

M

N

P

Q

R

S

T

Z